Biopsy Devices Market, By Product Type (Procedure Tray, Needle Based Biopsy Instruments, Liquid Biopsy Instruments, Biopsy Table, Biopsy Forceps, Others), By Biopsy Type (Bone marrow biopsy, Cone biopsy, Excisional biopsy, Liquid biopsy, Needle biopsy, Others), By Application (Prostate, Endometrial, Liver, Heart, Others), By End User (Hospital, Diagnostic Labs, Academic & Research Institutes), By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

Published In : Dec 2023

Code : CMI220

Pages :180

Formats :

Excel and PDF

Industry : Medical Devices

Market News

Global Biopsy Devices Market Recent Developments

In December 2022, Agilent Technologies Inc. announced that the U.S. FDA approved Agilent Resolution ctDx FIRST as a companion diagnostic (CDx) for identifying advanced non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations who may benefit from treatment with KRAZATITM (adagrasib). This is the first liquid biopsy NGS test approved by the U.S. FDA as a CDx for the recently licensed KRAZATI in advanced NSCLC, and it was developed in partnership with Mirati Therapeutics, a targeted oncology business focused on cancer treatment research.
In October 2022, nRichDX, an emerging leader in sample preparation solutions, announced the launch of two new products to assist researchers in the development of liquid biopsy assays. Both products are intended for use with the nRichDX Revolution Sample Prep System.
In September 2022, Guardant Health, Inc., a leading precision oncology company, announced the launch of GuardantINFINITY, a next-generation liquid biopsy that provides new, multi-dimensional insights into the complexities of tumor molecular profiles and immune responses to advance cancer research and therapy development.

Collaborations and Partnerships:

On April 14, 2023, Agena Bioscience, a Mesa Labs, Inc. subsidiary, and nRichDX expanded their existing technical collaboration into a commercial collaboration that will co-promote their products to researchers developing liquid biopsy applications on the Agena MassARRAY platform.
On March 27, 2023, nRichDX and OraSure Technologies, Inc., a medical device company, expanded a commercial partnership to validate and co-promote their products for researchers developing liquid biopsy applications using first-void urine samples. Notably, first-void urine is rich in indicators useful for molecular investigation in applications such as sexually transmitted infections, human papillomavirus, and early stage cancer.
In October 2020, Epic Sciences, Inc., a cancer diagnostics company, and Predicine, Inc., a global molecular insights company, announced a global strategic partnership to provide biopharmaceutical companies with access to both Predicine's ctDNA-based testing and Epic's CTC-based testing. Predicine, Inc. is a molecular insights firm based in California, U.S., that has developed an NGS liquid biopsy technique for measuring ctDNA and ctRNA genomic alterations in blood or urine.